Determination of trimethylamine-N-oxide in combination with L-carnitine and γ-butyrobetaine in human plasma by UPLC/MS/MS.
暂无分享,去创建一个
G. Latkovskis | I. Konrāde | E. Liepinsh | S. Grinberga | O. Pugovics | M. Dambrova | Eduards Sevostjanovs | I. Strele | D. Hartmane
[1] S. Hazen,et al. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. , 2014, Cell metabolism.
[2] E. Liepinsh,et al. Risks and benefits of carnitine supplementation in diabetes. , 2014, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[3] E. Liepinsh,et al. Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availability of l-carnitine and to reduce myocardial infarct size. , 2014, Pharmacological research.
[4] S. Hazen,et al. Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. , 2014, Analytical biochemistry.
[5] G. Lopaschuk,et al. Gut microbiota metabolism of L-carnitine and cardiovascular risk. , 2013, Atherosclerosis.
[6] R. Petrovska,et al. Meldonium decreases the diet‐increased plasma levels of trimethylamine N‐oxide, a metabolite associated with atherosclerosis , 2013, Journal of clinical pharmacology.
[7] J. DiNicolantonio,et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. , 2013, Mayo Clinic proceedings.
[8] F. Bushman,et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.
[9] I. Konrāde,et al. Mildronate treatment alters γ‐butyrobetaine and l‐carnitine concentrations in healthy volunteers , 2011, The Journal of pharmacy and pharmacology.
[10] Brian J. Bennett,et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.
[11] A. Lesimple,et al. Measurement of urinary trimethylamine and trimethylamime oxide by direct infusion electrospray quadrupole time-of-flight mass spectrometry. , 2010, Analytical biochemistry.
[12] U. Spiekerkoetter,et al. ESI-MS/MS measurement of free carnitine and its precursor γ-butyrobetaine in plasma and dried blood spots from patients with organic acidurias and fatty acid oxidation disorders. , 2010, Molecular genetics and metabolism.
[13] Sangkyun Lee,et al. Determination of Urinary Trimethylamine and Trimethylamine N-oxide by Liquid Chromatography-Tandem Mass Spectrometry Using Mixed-Mode Stationary Phases , 2010 .
[14] K. Eder,et al. Determination of carnitine, its short chain acyl esters and metabolic precursors trimethyllysine and gamma-butyrobetaine by quasi-solid phase extraction and MS/MS detection. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[15] R. Milne,et al. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] T. Annesley. Ion suppression in mass spectrometry. , 2003, Clinical chemistry.
[17] H. Nakajima,et al. Measurement of carnitine precursors, ε-trimethyllysine and γ-butyrobetaine in human serum by tandem mass spectrometry , 1999 .
[18] E. Lukevics,,et al. Betaines derived from amino and hydrazino acids as phase transfer catalysts , 1990 .